Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. - Wikidata - awgldk - TriplyDB

Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.

Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.

http://www.wikidata.org/entity/Q35116804

about

Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells The Repurposing Drugs in Oncology (ReDO) Project.Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control.Pilot study of a pediatric metronomic 4-drug regimen.Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, Argentina Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence.Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child.Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report.Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma.A Composite Synergistic Systems Model for Exploring the Efficacies of Different Chemotherapeutic Strategies in Cancer

P2860

Q27015786-E98969EF-8654-42FB-8910-3486F702647A Q27023579-DC4370C7-FC29-4C5C-998A-251482835F5B Q28553176-B62AFC7E-522A-4D70-913A-68E12876B5D6 Q33893949-04D5B008-F79B-4114-BEF0-EA92DED7CCE4 Q35284185-0187F73B-98E1-4DB2-A8D3-E41C89F0CB5B Q35764422-33B3A09F-1956-46B1-AE0B-A18411030851 Q37236004-2B55D659-1F43-4CE7-93BB-1523293714B7 Q37239002-C1EA225F-0053-4F30-A7E5-B6E27E495E2B Q38014527-EE1473D8-5C50-4EA0-8437-2CF40361CEB5 Q38155883-3CD0BCDC-F54E-46B8-A88F-246459999B6F Q39217689-14F00287-C5A2-4AA2-9E76-DAEBE761B398 Q39300990-DCA68E71-B648-4FF9-BDA9-892331480C0A Q41912972-A1B20C0D-7F30-4962-B275-401C6034C787 Q43056415-A790FE1A-E8EE-4D2D-BAA3-05EA03FA3237 Q46127435-2F9C2971-8E88-4F8D-A305-B5B1AB050E5A Q47845685-5FA6752D-C49A-4184-8784-3820B0F4681C Q53655244-D1D044EB-1222-467B-902E-898974D8F2AE Q58919527-5B3A2B6E-A41E-40DA-988A-34465E869E6D

P2860

Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.

http://www.wikidata.org/entity/Q35116804

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Moving forward with metronomic ...... herapy in Paediatric Oncology.

@ast

Moving forward with metronomic ...... herapy in Paediatric Oncology.

@en

type

label

Moving forward with metronomic ...... herapy in Paediatric Oncology.

@ast

Moving forward with metronomic ...... herapy in Paediatric Oncology.

@en

prefLabel

Moving forward with metronomic ...... herapy in Paediatric Oncology.

@ast

Moving forward with metronomic ...... herapy in Paediatric Oncology.

@en

P1433

Q35116804-BE774F3E-6554-46A8-96E2-DE48FE1A2F6A

P1476

Q35116804-AE0AACB0-FE73-426B-8EE8-0726E5A7D376

P2093

Q35116804-01784F49-A912-446C-9271-C97F7C376551

Q35116804-19069114-706B-4305-86B5-77B995CC249C

Q35116804-2A9E8A9D-7F03-4C03-848C-68E055C88DAD

Q35116804-52BB6DB9-90DD-46CB-A518-6ED9740BDA0E

Q35116804-6EEC404C-8D5D-4E99-BECC-966347B5AFA9

Q35116804-9EA84A7D-D1DD-439E-AFB8-434F56BF8DBC

Q35116804-A7EF9603-4853-402E-83E1-DD66036AD9C5

Q35116804-B43B175F-74DD-4320-8802-503E48A98D0F

Q35116804-C418B17F-7CA9-4593-A89E-BD781A6C7F7F

Q35116804-C6D50110-1BBA-4819-81DE-54387C21F930

P2860

Q35116804-06322346-2C49-4651-B0C8-FD5850F9830F

Q35116804-0655B2D4-5D08-401A-81DE-25B2630036B5

Q35116804-0DACDC16-D4C6-46AA-AC9A-3FD492077FE4

Q35116804-0DE133ED-0A31-4016-93DE-138FC5D701A0

Q35116804-1357F619-C0F7-44DF-B650-E1606C871E15

Q35116804-17CFCDC5-5A98-446F-B5E6-A280D4BEA21B

Q35116804-1B313BE2-BC2F-4701-84B3-4AFC0B91C7C2

Q35116804-1D1E5EE7-B483-45D3-A3C7-C51888772170

Q35116804-244557B0-6A45-49D4-B588-07F7079DA90B

Q35116804-2976C9B0-07EF-4AC6-8877-CBF1851DA96E

P304

Q35116804-0727BD91-D4F8-405F-93E3-46EBB3217CF7

P31

Q35116804-7EC4F248-1BFF-4A09-A9F6-69DC31C5DB4A

P356

Q35116804-6C12678E-718A-47DF-8CDE-31209B793C64

P433

Q35116804-A15EAB3D-BFD8-4061-AFEB-2EED7304D88E

P478

Q35116804-F1F6E77C-D34E-4505-8BA4-C78EF77938D9

P50

Q35116804-291C9D58-F915-4BD4-A0FC-04D4B4EFF6EA

Q35116804-4D3E809A-6945-4513-8FE0-460946E1DCBC

Q35116804-D8678084-2750-4F72-A47A-944C6EB3A70D

P577

Q35116804-749E63FF-E126-4B97-87D0-6380D70B8FB2

P5875

Q35116804-49B0895A-336C-407C-85FF-2DCEDF6C6ECC

P698

Q35116804-0FEE876D-34FF-4613-B2B1-E3F5667A24AF

P921

Q35116804-044B44FC-378E-4CFE-9C95-0F47540EE569

Q35116804-6AFE0A24-FB43-40D4-AB37-E02A94260095

P932

Q35116804-06A283E6-6840-4009-B7A4-13A78EED8576

P356

P1433

Translational Oncology

P1476

Moving forward with metronomic ...... therapy in Paediatric Oncology

@en

P2093

Andreas Peyrl

http://www.w3.org/2001/XMLSchema#string

Arnauld Verschuur

http://www.w3.org/2001/XMLSchema#string

Franck Berthold

http://www.w3.org/2001/XMLSchema#string

Gilles Vassal

http://www.w3.org/2001/XMLSchema#string

Jaroslav Sterba

http://www.w3.org/2001/XMLSchema#string

Mamouna Diawarra

http://www.w3.org/2001/XMLSchema#string

Maria Sanna Kivivuori

http://www.w3.org/2001/XMLSchema#string

Nicolas André

http://www.w3.org/2001/XMLSchema#string

Odile Oberlin

http://www.w3.org/2001/XMLSchema#string

Stergios Zacharoulis

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma.

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.

Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children.

A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma.

Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.

P304

203-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/TLO.11124

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Michela Casanova

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51536165

http://www.w3.org/2001/XMLSchema#string

P698

21804915

http://www.w3.org/2001/XMLSchema#string

P921

P932

3140007

http://www.w3.org/2001/XMLSchema#string